ARAF and thyroid gland carcinoma: Since sorafenib is already an FDA-approved therapy for hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer [10,11,12] with a well-characterized safety profile, it could readily be repurposed as a targeted therapy in the specific lung cancer subgroup harboring the ARAF p.S214C mutation without the need for the extensive safety trials typically required for novel drugs.